Výsledky vyhledávání - "Ulrich Wendisch"

1023-P: Do Baseline Characteristics Impact Efficacy of Efpeglenatide QW in Uncontrolled Type 2 Diabetes?

Autor: George E. Dailey, Christopher H. Sorli, In Young Choi, Ulrich Wendisch, Jahoon Kang, Marcus Hompesch, John A. Stewart, Cristobal Morales, Michael E. Trautmann, Ike Ogbaa, Kun-Ho Yoon, Julio Rosenstock

Publikováno v: Diabetes. 68

Once-weekly (QW), subcutaneous efpeglenatide (EFPEG) is a long-acting GLP-1 RA for T2D management. In EXCEED 203 (NCT02057172), EFPEG QW significantly reduced HbA1c vs. placebo (PBO) for early T2D (naïve/metformin monotherapy). This post hoc subanal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7d4aecd83bfcfb614d9479c915390508
https://doi.org/10.2337/db19-1023-p

Zobrazit plný text záznamu

1014-P: Relationship between Glycemic Control and Weight Loss with Once-Weekly Efpeglenatide in Uncontrolled Type 2 Diabetes: A Subanalysis of EXCEED 203

Autor: Julio Rosenstock, Christopher H. Sorli, In Young Choi, Marcus Hompesch, Kun-Ho Yoon, John A. Stewart, Cristobal Morales, Ike Ogbaa, Michael E. Trautmann, Ulrich Wendisch, Jahoon Kang, George E. Dailey

Publikováno v: Diabetes. 68

Efpeglenatide (EFPEG) is a long-acting GLP-1 RA, administered by once-weekly (QW) subcutaneous injection, currently being developed to improve glycemic control in patients with T2D. EXCEED 203 (NCT02057172), a 12-week study of EFPEG (0.3, 1, 2, 3, or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b7401b2b4fc02c6259773dc88e62698e
https://doi.org/10.2337/db19-1014-p

Zobrazit plný text záznamu

Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide

Autor: Cristobal Morales, Ulrich Wendisch, Julio Rosenstock, George Dailey, Christopher H. Sorli, In Young Choi, Marcus Hompesch, Jahoon Kang, Kun-Ho Yoon, Michael E. Trautmann, John A. Stewart

Publikováno v: Diabetes care. 42(9)

OBJECTIVE To explore the efficacy, safety, and tolerability of once-weekly efpeglenatide, a long-acting glucagon-like peptide 1 receptor agonist (GLP-1 RA), in early type 2 diabetes (T2D) (drug naive or on metformin monotherapy). RESEARCH DESIGN AND

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c27c3008e5006dcacf4ad10188abb2a
https://pubmed.ncbi.nlm.nih.gov/31320446

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání